Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

PHASE1RecruitingINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions

Overweight

Interventions

DRUG

HU6

HU6 tablet or capsule

Trial Locations (1)

RECRUITING

Nucleus Network, Minneapolis

All Listed Sponsors

lead

Rivus Pharmaceuticals, Inc.

INDUSTRY

NCT07170189 - Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6 | Biotech Hunter | Biotech Hunter